A Phase 2 interventional study of NNC0519-0130 and Placebo in Obesity, sponsored by Novo Nordisk A/S. Completed at 70 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 47th largest by enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2024, is one of 13 in phase 2, and was the 122nd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 14 · Phase 3 62 · Phase 4 4
First in 2007; this study’s year is marked. 22 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 354 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 138 across the 166 interventional studies, 1,260 across the 41 observational. Of the 138 that completed or were terminated, 39 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
26 of the studies in Obesity by Novo Nordisk A/S that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
Add all 26 to your calendar (.ics) → With an account.
Among the 207 studies in Obesity by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female of non-, or male.
a. For US only: Female of childbearing potential using highly effective non-systemic methods of with low user-dependency at least 2 months prior to screening and willingness to continue using it through-out the study, or male.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive NNC0519-0130 at 1 dose level subcutaneously (s.c.) once-weekly up to 36 weeks.
Drug: NNC0519-0130
Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
Drug: Placebo
Participants will receive NNC0519-0130 at 2 dose levels s.c. once-weekly up to 36 weeks.
Drug: NNC0519-0130
Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
Drug: Placebo
Participants will receive NNC0519-0130 at 3 dose levels s.c. once-weekly up to 36 weeks.
Drug: NNC0519-0130
Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
Drug: Placebo
Participants will receive NNC0519-0130 at 4 dose levels s.c. once-weekly up to 36 weeks.
Drug: NNC0519-0130
Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
Drug: Placebo
Participants will receive NNC0519-0130 at 5 dose levels s.c. once-weekly up to 36 weeks.
Drug: NNC0519-0130
Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
Drug: Placebo
Participants will receive NNC0519-0130 at 6 dose levels s.c. once-weekly up to 36 weeks.
Drug: NNC0519-0130
Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
Drug: Placebo
Participants will receive tirzepatide at 6 dose levels s.c. once weekly up to 36 weeks.
Drug: Tirzepatide
NNC0519-0130 will be administered subcutaneously.
Placebo will be administered subcutaneously.
Tirzepatide will be administered subcutaneously.
Relative change in body weight
Measured in percentage of body weight.
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in body weight
Measured in kilograms (kg)
Time frame: From baseline (week 0) to end of treatment (week 36)
Achievement of greater than equal to (≥) 5% weight reduction
Count of participants
Time frame: From baseline (week 0) to end of treatment (week 36)
Achievement of ≥ 10% weight reduction
Count of participants
Time frame: From baseline (week 0) to end of treatment (week 36)
Achievement of ≥ 15% weight reduction
Count of participants
Time frame: From baseline (week 0) to end of treatment (week 36)
Achievement of ≥ 20% weight reduction
Count of participants
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in body mass index (BMI)
Measured in Kilogram per meter square (Kg/m\^2)
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in waist circumference
Measured in centimeter (cm)
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in glycated hemoglobin (HbA1c)
Measured in percentage point (%-point)
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
Measured in millimoles per liter (mmol/L)
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in systolic blood pressure (SBP)
Measured in milliters of mercury (mmHg)
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in high sensitivity C-Reactive protein (hsCRP)
Ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in total cholesterol
Ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in high-density lipoprotein (HDL) cholesterol
Ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in low-density lipoprotein (LDL) cholesterol
Ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in triglycerides
Ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) Physical composite score
IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in IWQOL-Lite-CT Psychosocial composite score
IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in IWQOL-Lite-CT Physical Function score
IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).
Time frame: From baseline (week 0) to end of treatment (week 36)
Change in IWQOL-Lite-CT Total score
IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).
Time frame: From baseline (week 0) to end of treatment (week 36)
Number of adverse events
Count of events
Time frame: From baseline (week 0) to end of treatment (week 40)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Apr 2025, 12 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 12 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NNC0519-0130